
Astec LifeSciences (ASTEC) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
910.8M
Gross Profit
272.0M
29.86%
Operating Income
-224.8M
-24.68%
Net Income
-330.3M
-36.26%
EPS (Diluted)
₹-16.72
Balance Sheet Metrics
Total Assets
8.8B
Total Liabilities
6.5B
Shareholders Equity
2.4B
Debt to Equity
2.75
Cash Flow Metrics
Revenue & Profitability Trend
Astec LifeSciences Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 3.8B | 4.6B | 6.3B | 6.8B | 5.5B |
Cost of Goods Sold | 3.0B | 3.2B | 4.1B | 3.9B | 3.5B |
Gross Profit | 785.9M | 1.3B | 2.2B | 2.9B | 2.1B |
Gross Margin % | 20.6% | 29.4% | 35.5% | 42.2% | 37.8% |
Operating Expenses | |||||
Research & Development | 21.4M | 27.0M | 14.9M | 9.1M | 9.2M |
Selling, General & Administrative | 123.7M | 97.6M | 197.7M | 189.8M | 129.0M |
Other Operating Expenses | 677.9M | 649.1M | 709.9M | 598.4M | 447.3M |
Total Operating Expenses | 823.0M | 773.7M | 922.4M | 797.3M | 585.6M |
Operating Income | -1.1B | -415.9M | 435.3M | 1.2B | 897.1M |
Operating Margin % | -28.8% | -9.1% | 6.9% | 17.8% | 16.2% |
Non-Operating Items | |||||
Interest Income | 8.0M | 1.5M | 40.5M | 2.6M | 7.8M |
Interest Expense | 362.8M | 248.6M | 201.6M | 86.9M | 47.5M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -1.4B | -617.5M | 349.5M | 1.2B | 890.7M |
Income Tax | -62.8M | -148.6M | 93.5M | 312.4M | 240.0M |
Effective Tax Rate % | 0.0% | 0.0% | 26.8% | 25.8% | 26.9% |
Net Income | -1.3B | -468.9M | 255.9M | 898.8M | 650.7M |
Net Margin % | -35.3% | -10.2% | 4.1% | 13.3% | 11.7% |
Key Metrics | |||||
EBITDA | -636.4M | -5.3M | 891.6M | 1.6B | 1.2B |
EPS (Basic) | ₹-68.19 | ₹-23.93 | ₹13.04 | ₹45.87 | ₹33.23 |
EPS (Diluted) | ₹-68.19 | ₹-23.93 | ₹13.04 | ₹45.85 | ₹33.21 |
Basic Shares Outstanding | 19760921 | 19607450 | 19603024 | 19589899 | 19575811 |
Diluted Shares Outstanding | 19760921 | 19607450 | 19603024 | 19589899 | 19575811 |
Income Statement Trend
Astec LifeSciences Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 5.8M | 4.7M | 4.7M | 5.5M | 3.4M |
Short-term Investments | 2.8M | 11.8M | 2.5M | 27.9M | 12.0M |
Accounts Receivable | 1.5B | 1.7B | 1.5B | 2.7B | 1.9B |
Inventory | 1.6B | 2.0B | 2.9B | 1.9B | 1.1B |
Other Current Assets | 2.0K | 6.0K | 2.0K | 2.0K | 113.0K |
Total Current Assets | 3.4B | 4.0B | 5.0B | 5.2B | 3.3B |
Non-Current Assets | |||||
Property, Plant & Equipment | 317.4M | 245.4M | 172.6M | 169.6M | 54.3M |
Goodwill | 234.5M | 194.2M | 159.0M | 113.9M | 51.6M |
Intangible Assets | 234.5M | 194.2M | 159.0M | 113.9M | 51.6M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 105.2M | -1.0K | -2.0K | 129.8M | 1.0K |
Total Non-Current Assets | 5.4B | 5.8B | 4.8B | 3.8B | 3.5B |
Total Assets | 8.8B | 9.7B | 9.8B | 9.0B | 6.8B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 816.1M | 892.8M | 1.8B | 1.9B | 1.3B |
Short-term Debt | 2.7B | 2.9B | 3.3B | 2.8B | 1.5B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 18.0K | 11.0K | 77.0K | 41.0K | 69.0K |
Total Current Liabilities | 3.7B | 4.0B | 5.3B | 4.9B | 3.2B |
Non-Current Liabilities | |||||
Long-term Debt | 2.8B | 2.0B | 108.6M | 0 | 400.0M |
Deferred Tax Liabilities | 380.0K | 67.6M | 209.7M | 80.8M | 54.7M |
Other Non-Current Liabilities | - | - | 13.5M | - | - |
Total Non-Current Liabilities | 2.8B | 2.1B | 336.6M | 95.1M | 459.9M |
Total Liabilities | 6.5B | 6.1B | 5.6B | 5.0B | 3.7B |
Equity | |||||
Common Stock | 196.1M | 196.1M | 196.1M | 196.0M | 195.9M |
Retained Earnings | 1.4B | 2.8B | 3.3B | 3.0B | 2.2B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 2.4B | 3.7B | 4.2B | 4.0B | 3.1B |
Key Metrics | |||||
Total Debt | 5.5B | 4.9B | 3.4B | 2.8B | 1.9B |
Working Capital | -245.7M | 13.3M | -273.5M | 250.9M | 81.5M |
Balance Sheet Composition
Astec LifeSciences Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -1.4B | -617.5M | 349.5M | 1.2B | 890.7M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 345.0K | 3.0M | 3.3M | 1.0M | 99.0K |
Working Capital Changes | 345.1M | 994.9M | 83.1M | -1.7B | -366.8M |
Operating Cash Flow | -705.5M | 631.1M | 602.5M | -427.8M | 563.7M |
Investing Activities | |||||
Capital Expenditures | -158.5M | -1.4B | -1.2B | -1.0B | -1.0B |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | -2.8M | -1.1M | - | -324.0K |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -158.5M | -1.4B | -1.2B | -1.0B | -736.9M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | -29.4M | -29.4M | -29.4M | -29.4M |
Debt Issuance | 1.5B | 2.0B | 1.4B | 0 | 883.5M |
Debt Repayment | -607.6M | -439.6M | -1.3B | 0 | - |
Financing Cash Flow | 622.9M | 2.0B | 578.4M | 893.9M | 1.3B |
Free Cash Flow | -302.2M | -1.3B | -426.0M | -803.7M | -1.1B |
Net Change in Cash | -241.2M | 1.3B | 13.8M | -572.5M | 1.2B |
Cash Flow Trend
Astec LifeSciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
399.52
Forward P/E
20.05
Price to Book
6.77
Price to Sales
4.48
PEG Ratio
-22.88
Profitability Ratios
Profit Margin
-31.78%
Operating Margin
-24.68%
Return on Equity
-57.34%
Return on Assets
-15.29%
Financial Health
Current Ratio
0.93
Debt to Equity
235.96
Beta
0.06
Per Share Data
EPS (TTM)
₹-64.81
Book Value per Share
₹119.70
Revenue per Share
₹205.54
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
astec | 18.1B | 399.52 | 6.77 | -57.34% | -31.78% | 235.96 |
Coromandel | 693.7B | 30.68 | 6.25 | 18.41% | 8.56% | 6.95 |
UPL | 622.8B | 3.00 | 1.63 | 2.01% | 0.09% | 105.06 |
Bharat Rasayan | 45.8B | 33.33 | 4.05 | 12.47% | 10.84% | 7.54 |
National Fertilizers | 45.0B | 24.47 | 1.66 | 6.77% | 0.84% | 73.68 |
Mangalore Chemicals | 40.7B | 25.19 | 3.83 | 13.50% | 4.78% | 69.63 |
Financial data is updated regularly. All figures are in the company's reporting currency.